The role of interleukin 12 and nitric oxide in the development of spontaneous autoimmune disease in MRLMP-lprlpr mice by unknown
The Role of Interleukin 12  and Nitric  Oxide 
in the Development of Spontaneous Autoimmune 
Disease in MRL/MP-lpr/lpr Mice 
By Fang-Ping Huang, Gui-Jie Feng, George Lindop,* David I. Stott, 
and FooY. Liew 
From the Department of Immunology and *Pathology, University of Glasgow, Glasgow G11 6NT, 
United Kingdom 
Summary 
MR_L/MP-lpr/lpr  (MRL/lpr)  mice develop a spontaneous  autoimmune disease.  Serum from 
these mice contained significantly higher concentrations of nitrite/nitrate than serum from age- 
matched control MRL/MP-+/+  (MRL/+), BALB/c or CBA/6J mice. Spleen and perito- 
neal cells from MRL/Ipr mice also produced significantly more nitric oxide (NO) than those 
from the control mice when cultured with interferon (IFN) ~/and lipopolysaccharide (LPS) in 
vitro. It is interesting to note that peritoneal cells from MRL/lpr mice also produced markedly 
higher concentrations of interleukin (IL) 12 than those from MRL/+  or BALB/c mice when 
cultured with the same stimuli. It is striking that cells from MRL/Ipr mice produced high con- 
centrations of NO when cultured with IL-12 and LPS, whereas only low or background levels 
of NO  were produced by similarly cultured cells from MRL/+  or BALB/c mice. The en- 
hanced NO  synthesis induced by IFN-'y/LPS was substantially inhibited by anti-IL-12 anti- 
body. In addition, IL-12-induced NO production can also be markedly inhibited by anti-IFN-~ 
antibody, but only weakly inhibited by anti-tumor necrosis factor c~ antibody. The effect of 
IL-12 on NO production was dependent on the presence of natural killer and possibly T  cells. 
Serum from MRL/Ipr mice contained significantly higher concentrations of IL-12 compared 
with those of MRL/+  or BALB/c control mice. Daily injection of recombinant IL-12 led to 
increased serum levels of IFN-~/ and NO  metabolites, and accelerated glomerulonephritis in 
the young MRL/Ipr mice (but not in the MRL/+  mice) compared with controls injected with 
phosphate-buffered saline  alone. These data, together with previous finding that NO synthase 
inhibitors can ameliorate autoimmune disease in MRL/Ipr mice, suggest that the high capacity 
of such mice to produce IL-12 and their greater responsiveness to IL-12, leading to the pro- 
duction of high concentrations of NO, are important factors in this spontaneous model of au- 
toimmune disease. 
M 
RL/MP-lpr/Ipr  (MRL/Ipr) 1 mice develop a sponta- 
neous autoimmune disease  and have been used ex- 
tensively as a model for clinical SLE. The disease is charac- 
terized by lymphadenopathy, autoantibody production, and 
inflammatory manifestations such as nephritis, vasculitis,  and 
arthritis (1, 2). The cause of the disease is likely to be mul- 
tifactorial, including a single  gene mutation (Ipr) of the fas 
apoptosis gene on mouse chromosome 19 (3, 4) and back- 
ground genes from the MRL strain (1, 4). 
Recent studies show that MRL/Ipr mice excreted signif- 
icantly higher concentrations of urinary nitrate/nitrite than 
age-matched normal C3H mice  (5).  Furthermore, MRL/ 
1Abbreviations used in this  paper: HRP, horseradish peroxidase; L-NMMA, 
L-N  G  monomethyl  arginine; MRL/lpr, MRL/MP-lpr/lpt;, NO, nitric ox- 
ide; NOS, nitric oxide  synthase. 
lpr mice showed markedly reduced proteinuria and mini- 
real glomemlar proliferation when treated orally with L-N  G 
monomethyl arginine  (L-NMMA),  an  inhibitor  of nitric 
oxide synthase  (NOS)  (5).  These  data  therefore strongly 
suggest that nitric oxide (NO) is an important mediator of 
the disease  manifestation of MRL/lpr mice. However, the 
mechanism(s) for this exaggerated NO synthesis by MRL/ 
lpr mice remains obscure. 
NO is a critical mediator of a variety of biological func- 
tions,  including  vascular  relaxation,  platelet  aggregation, 
neurotransmission,  tumoricidal  and  microbicidal  activity, 
and immunosuppression  (6-10).  It is  also  implicated in a 
range of immunopathologies (11-13). NO is derived from 
the guanidino nitrogen atom(s) (14) and molecular oxygen 
(15,  16) in a reaction catalyzed by the enzyme NOS. There 
are three major isoforms of NOS  (17):  the neuronal form 
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Volume 183 April 1996 1447-1459 (nNOS)  and  the  endothelial  form  (eNOS)  produce  the 
amounts  of NO  required for physiological functions.  The 
cytokine-inducible form (iNOS) is induced by a number of 
immunological stimuli, such  as IFN-%  TNF-~x,  and LPS, 
and catalyzes the high  output  of NO  which  can be  cyto- 
toxic. 
Since  the  expression and  functional activities of IFN-y 
and TNF-or  in SLE and its animal models are highly vari- 
able and controversial (18,  19), we explored the possibility 
that the  exaggerated NO  synthesis in MP,  L/lpr mice may 
be due  to enhanced production of other factor(s). We re- 
port  here  that  spleen  and  peritoneal cells from  MILL/Ipr 
mice produced significantly higher concentrations of lL-12 
than  those  from  the  control  MP,  L/+,  or  BALB/c  mice 
when  stimulated with LPS and IFN-'y in vitro. IL-12 and 
LPS synergistically stimulated the spleen and peritoneal cells 
from  MILL/lpr mice,  but  not  from  the  control  MR.L/+ 
mice, to produce high levels of NO.  Furthermore, young 
M1LL/Ipr  mice  developed  accelerated  glomerulonephritis 
when injected with rlL-12 compared with control injected 
with  PBS  alone.  Thus,  the  enhanced  capacity to produce 
IL-12 and the higher responsiveness to IL-12/LPS to pro- 
duce NO may play an important role in the pathogenesis of 
MRL/Ipr mice. 
Materials and Methods 
Mice.  Female MILL/Ipr  and  age-  and  sex-matched  control 
MRL/MP-+/+,  BALB/c,  and  CBA/6J  mice  were  obtained 
from Harlan Olac Ltd.  (Bicester, UK).  Some of the mice were 
bred in the  animal facilities, University of Glasgow, from pairs 
obtained from Harlan Olac. They were housed in a conventional 
animal facility. 
Cytokines and Reagents.  Murine rlFN-"/was a kind gift of Dr. 
G. Adolf (Bender, Vienna, Austria). Murine rlL-12 and mono- 
clonal (clones C15.6  and C15.1.2)  and polyclonal (sheep  no. 7) 
anti-IL-12 antibodies were generously provided by Dr. Stan Wolf 
(Genetic  Institute,  Boston,  MA).  Polyclonal  anti-IL-12,  anti- 
IFN-y, and anti-TNF-oe antibodies were raised in rabbits immu- 
nized with murine rlL-12, rlFN-y, or TNF-cx, respectively using 
a  standard  protocol.  Monodonal  anti-CD4  (YTS191)  and  anti- 
CD8 (YTS169)  were kindly provided by Dr. H. Waldmann (Uni- 
versity of Oxford, Oxford, UK). Monoclonal anti-NK antibody 
(5E6,  endotoxin removed) was obtained from PharMingen (San 
Diego,  CA). Monoclonal anti-Thyl.2 (F7D5)  was obtained from 
Olac Ltd. Fresh rabbit serum was used as a source of complement. 
t-NMMA  and  D-NMMA  were  kindly  provided  by  Dr.  S. 
Moncada  (Glaxo Wellcome Research  Laboratory, Beckenham, 
UK). LPS (Salmonella enteriticlis) and Con A  were obtained from 
Sigma (Poole, UK). 
Mouse Peritoneal and Spleen Cell Preparation.  Peritoneal cells were 
collected by injecting 5-7 ml of ice-cold PBS into the peritoneal 
cavity before harvesting and kept on ice before use. Spleen was 
then removed and a single cell suspension prepared by gently forc- 
ing the spleen through a sterile tea strainer into a petri dish in 
HBSS (Gibco, Paisley, UK) containing 1% FCS. The cells were then 
washed in serum-free HBSS and viability determined by trypan 
blue exclusion. 
Cell Depletion.  Single cell suspensions (107 cells/m]) in PBS 
were incubated on ice for 30 min with anti-CD4, anti-CD8 (hy- 
bridoma culture supernatant,  1:1 dilution), anti-NK (5E6,  5 p.g/ 
nal), anti-Thyl.2 (ascites, 1:500 dilution) or anti-Thyl.2, plus anti- 
NK. After 2 washes with ice-cold PBS, the cells were incubated 
with or without rabbit complement (1:20) in 96-well culture plates 
for 45 min at 37~  at 2  X  10  s cells/well in 100  p.1 of cornplete 
culture medium  (P,  PMI  1640;  Gibco)  supplemented with  10% 
heat-inactivated FCS, 50 U/ml penicillin, 50 p-g/ml streptomy- 
cin, and 50 ~M 2-mercaptoethanol). Cells were then pelleted by 
centrifugation of the plate and the supernatant was  carefully re- 
moved. The incubation was repeated with fresh complement and 
followed by two washes with warm medium. Samples of the re- 
sidual cells were phenotyped in parallel tubes by flow cytometry 
(Becton Dickinson & Co.) using FITC- or PE-conjugated anti- 
bodies to  CD4,  CD8  (13ecton Dickinson &  Co.,  Oxford,  UK) 
and CD3 (PharMingen). 
Ceil Culture.  Spleen  (2  ￿  105  viable cells/well) or resident 
peritoneal cells (1.5-3  ￿  105 cells/well, varied between different 
experiments) in 200 p-1 were cultured in full medium in 96-well 
plates (Nunc, Roskilde, Denmark) at 37~  and 5% CO2 for up to 
6  d.  To  stimulate for NO  synthesis,  graded doses of IL-12 and 
LPS were titrated and optimal doses determined. IFN-y was used 
at  50  U/ml  unless  indicated otherwise.  To  stimulate for  IL-12 
production, graded doses  of LPS  were  titrated with 50  U/ml of 
IFN-',/. In  the  antibody neutralization experiments,  cells were 
preincubated with specific antibodies to murine IL-12 (sheep no. 7 
or rabbit anti-IL-12), IFN-% or TNF-ot for 30 rain at 37~  be- 
fore the addition of stimulators. Concentrations of antibody used 
were  supraoptimal  for  neutralizing  the  amounts  of cytokines 
likely to be produced as determined in preliminary experiments. 
CytokineAssays.  IL-12 concentration was determined by an 
ELISA method using a combination of two rat monoclonal anti- 
bodies (C15.1.2  and C15.6,  Genetic  Institute) to  mouse  IL-12 
(p40  chain) as capture antibodies, and a sheep anti-mouse IL-12 
antibody (sheep no. 7) or a rabbit anti-mouse IL-12 (Rab.74.6) as 
detecting antibody. ELISA in 96-well plates (Immulon 4; Dyna- 
tech, Billingshurst, UK) was developed with a biotin-conjugated 
donkey anti-sheep IgG antibody (Sigma)  followed by StrepAvi- 
din-horseradish peroxidase (HRP) or a H1kP-conjugated donkey 
anti-rabbit IgG (SAPU,  Carluke, UK) accordingly, TMB  HRP 
substrate (KPL Laboratories, Gaithersburg, MD);  optical density 
was read on a Dynatech MR5000 ELISA reader at 630  nm.  Re- 
combinant murine IL-12 (Genetic Institute) was used as standard. 
Normal donkey serum (2%) was used as blocker. IL-12 produc- 
tion was also determined by Western blot. Peritoneal cells from 
four 13-wk-old MP,.L/Ipr mice were pooled and cultured at 2.5 
￿  105  cells/ml in  25-cm  2 flasks in  the  presence or absence of 
IFN-y (50  U/ml) and LPS  (i  p.g/m]).  Culture supernatant was 
harvested at 6,  12, 24, and 48 h, 3-ml samples were immune pre- 
cipitated with rat monoclonal anti-IL-12 antibodies (clones C 15.1.2, 
and C15.6, both against the p40 chain oflL-12), and the immune 
complexes  were  captured  by protein A-Sepharose beads.  The 
precipitate was then resolved on 10% SDS-PAGE and transferred 
to nitrocellulose membranes (Bio-Rad, Herts, UK). After block- 
ing with Tris-buffered saline containing 0.1%  Tween 20 and 2% 
BSA, the membrane was incubated sequentially with anti-IL-12 
antibody  (sheep  no.  7),  biotin-conjugated  donkey  anti-sheep 
IgG, and HRP-conjugated avidin, and protein bands visualized 
by the  enhanced  chemiluminescence (ECL)  system  (Amersham 
Biosciences, Amersham, Bucks,  UK). Recombinant murine  IL- 
12 was run in parallel with the test samples. 
The IFN-2t concentration was also determined by ELISA using 
a  rat  monoclonal  antibody  (R46AT)  and  a  rabbit anti-mouse 
IFN-~/antibody. The assay was developed with an alkaline phos- 
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phatase-conjugated  goat  anti-rabbit  IgG  antibody  (Sigma)  fol- 
lowed by p-nitrophenyl phosphate. Optical density was read on a 
Dynatech MtL700 ELISA reader at 410 nm. Recombinant murine 
IFN-',/was  used as standard.  In some experiments, an ELISPOT 
Figure  1.  Enhanced NO  syn- 
thesis in MRL/Ipr mice  in vivo 
and  in  vitro.  (a)  Serum nitrite/ 
nitrate  levels  in MRL/Ipr lupus 
strain (n =  47) and three control 
strains (n =  40) of mice at differ- 
ent ages. Total nitrite and nitrate 
concentration in  serum was de- 
termined by the nitrate reductase 
method which converted nitrate 
into  nitrite  before  measurement 
(see  Materials  and  Methods). 
LPS/IFN-'y-induced  NO  pro- 
duction by splenic (b-d) or peri- 
toneal  (e)  cells  from  young  (6- 
wk;  b and d)  and old  (25-wk;  c 
and  e)  MILL/Ipr,  MRL/+,  or 
BALB/c mice. Spleen or perito- 
neal  cells  from  three  mice  per 
group  were  pooled  and  stimu- 
lated  in  96-well  culture  plates 
with  IFN-y  (50  U/m])  and  ei- 
ther  1  b~g/m]  (b,  c,  and  e)  or 
graded doses (d) of LPS. In some 
cultures (d) L-NMMA (500 p,M) 
was added.  Culture supernatants 
were  collected  at  daily intervals 
and nitrite levels were measured 
by  the  Greiss  method.  Data 
shown are time course (b, c, and 
e), or (d) at day 6 as mean and SD 
of triplicate cultures.  (*P <0.05, 
**P  <0.01).  (d,  dotted line) Ni- 
trite  level  in  unstimulated  cul- 
tures. Consistent results were ob- 
tained in more than 10 repeated 
experiments. 
assay was also used to enumerate the number of IFN-~/--secreting 
cells. This was carried out as described previously (20). 
Assays for NO Production.  Total nitrate and nitrite concentra- 
tion  in  serum was determined by the  conversion  of nitrate into 
1449  Huang et al. nitrite as described previously (21). Briefly, serum samples (30 p~l) 
were incubated with an equal volume of reaction buffer contain- 
ing nicotinamide adenine dinucleotide phosphate (1 mg/ml), ra- 
vin adenine dinucleotide (8.3 mg/ml), KH2PO 4 (0.1 M), and ni- 
trate  reductase  (0.7  mg/ml;  Sigma),  added immediately before 
use.  Conversion was  carried out  at  37~  for 2  h  in  a  96-well 
ELISA plate  (Immulon 2;  Dynatech). Total nitrite content was 
then  measured  in  a  chemiluminescence  NO  analyzer  (Dabisi 
model 2107;  Quantitech Ltd., Milton Keynes, UK) according to 
the manufacturer's instruction. Nitrate standard was run in parallel 
with test samples. The assay was performed in triplicate and had a 
detection limit of 5  p~M. Nitrite concentration in culture super- 
natants was determined in triplicate by the Greiss reaction (22), 
using NaNO2 as standard with a detection limit of 1 b~M. 
Detection of Serum Autoantibodies by ELISA.  This was carried out 
as described previously (23) using single (ss) or double (ds) stranded 
calf thymus DNA (Sigma) as target antigens, Pooled serum from 
20-wk-old MRL/lpr mice of known high titer of anti-DNA anti- 
bodies was used as standard serum.  One  titration unit was arbi- 
trarily defined as the amount of antibody present in a fixed dilu- 
tion of the standard serum (1/10,000 for anti-ssDNA and 1/1,000 
for anti-dsDNA antibodies). 
Renal Histology.  Mouse kidney tissues were fixed in formalin 
and embedded in paraffin;  5-p~m sections were stained with peri- 
odic acid-Schiff. For histological examination by light microscopy, 
sections were randomly labeled and examined blind twice by two 
investigators. The  severity of kidney pathology was  assessed by 
the extent of enlargement of glomeruli and mesangial cell prolif- 
eration, tuft-to-capsule adhesions, protein casts in tubules, inter- 
stitial cellular infiltration, and vasculitis. 
Statistical Analysis.  Statistical significance (p value) was calcu- 
lated  by  the  Mann  Whitney  test  (Minitab  software  program; 
Minitab Inc., State College, PA). 
Results 
MRL/lpr Mice Produced Higher Concentrations of NO Me- 
tabolites than Normal Mice.  Serum from MRL/Ipr, MRs  +, 
BALB/c, and CBA mice of various ages were analyzed for 
NO  metabolites by converting nitrate  to  nitrite  and  then 
determining the total nitrite content. Serum from MRL/Ipr 
mice consistently contained significantly higher concentra- 
tions  of nitrate  and  nitrite  than  those  from  age-  and  sex- 
matched  MR.L/+,  BALB/c,  or  CBA/6J  mice  (Fig.  1  a). 
There was no significant difference between the concentra- 
tions of NO  metabolites produced by MRL/+,  BALB/c, 
or  CBA  mice.  These  results  therefore  confirm  previous 
findings (5)  that MRL/lpr mice produce exaggerated levels of 
NO in vivo. 
To  analyze  the  mechanism(s)  for  the  exaggerated pro- 
duction of NO  by the MP,.L/lpr mice, spleen (Fig. 1,  b-d) 
or peritoneal (Fig.  1  e)  cells from MRL/Ipr,  MR.L/+,  or 
BALB/c mice were cultured with IFN-y and LPS in vitro 
for up to  8  d,  and the concentrations of nitrite in the  cul- 
ture  supernatants  determined.  Cells  from  MR.L/Ipr  mice 
consistently  produced  significantly  higher  levels  of  NO 
than  similarly cultured cells from  age-matched young  (6- 
wk-old, Fig. 1,  b and d) or old (24-wk-old, Fig. 1, c and e) 
MRL/+,  or BALB/c  mice.  The  production  of NO  was 
LPS  dose  dependent  and  was  inhibitable  by  L-NMMA 
(Fig. 1 d). IFN-~/alone or LPS alone induced only a mini- 
mum level of NO synthesis by spleen cells (see Fig. 3, b and 
c). LPS alone did, however, induce significant levels of NO 
production by Ipr peritoneal cells (see Fig. 3  e). 
Peritoneal and Spleen Cells  from MRL/Ipr Mice Produce High 
Concentrations oflL-12.  We next investigated the produc- 
Figure  2.  Enhanced  IL-12  production  by  peritoneal 
calls from MkL/lpr mice.  Pooled  peritoneal  cells from 
three mice per group of MR.L/Ipr or MR.L/+  strains (2- 
3-mo-old)  were  cultured  in  the  presence or absence of 
IFN-~/ (50 U/ml) and LPS. IL-12 production  in the cell 
cultures (triplicates) was  determined  by ELISA: (a)  LPS 
dose-responses at day 4;  (b)  time  course with  1 txg/ml 
LPS. The data shown were representative of  three repeated 
experiments. (c) Western blot analysis  of IL-12 expression 
showed inducible IL-12 p40 chain (time course) identical 
to that of the rIL-12 control. The two distinct p40 bands 
may be due to different degrees of glycosylation  (24). 
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Figure 3.  Spleen and peritoneal cells from MILL/Ipr mice produced high concentrations of NO in response to rlL-12 and LPS. Pooled splenic (a-c) or 
peritoneal (d-f) cells from MtLL/Ipr, MILL/+, and BALB/c mice (3-mo-old, three mice per group) were stimulated in 96-well culture plates with or 
without fixed or different doses of rIL-12  and LPS.  Culture supernatants were  collected at  daffy intervals and nitrite levels measured by the Greiss 
1451  Huang et al. 20 
a 
15 
~o 
z 
........................ 
5  -  LPS alone 
I~___~  +  control  serum 
+  anti-lL-12 
b 
Y 
LPS alone 
medium control  <  7/JM  medium control  <  1 /~M 
........  I  ................  I  ........  I  ........  0 
10  100  .1  1  10  100 
100 
-75 
- 50 
- 25 
IFN ~  (U/ml) 
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oftriphcate cultures. (Dotted lines) Nitrite levels in cultures with LPS alone. Results from two repeated experiments were similar. (Note different scale for 
a and b). 
tion oflL-12, a powerful immune stimulatory cytokine, by 
the MRL/Ipr mice.  Peritoneal cells from  normal BALB/c 
or MR.L/+  mice produced only a low level oflL-12 when 
cultured with IFN-'y and LPS in vitro. By contrast, perito- 
neal cells from age-matched MRL/lpr mice produced up to 
10-fold more IL-12 when  cultured under identical condi- 
tions  (Fig.  2).  IL-12  production  by  the  cells of MRL/lpr 
mice was  LPS  dose- and time-dependent, reaching a  pla- 
teau level after 12 h  (Fig. 2,  b and c). LPS or IFN-~/alone 
induced minimum amounts  of IL-12 synthesis. Similar re- 
sults were obtained with spleen cells, except that the levels 
of IL-12 produced were lower (data not shown). 
Spleen and Peritoneal Cells  from MRL/Ipr Mice Produce High 
Levels of NO When Stimulated with IL-12 and LPS.  Subse- 
quent experiments were therefore carried out to investigate 
the  possible  link  between  IL-12  and  NO  synthesis  by 
MP,.L/lpr mice. Spleen cells from MRL/lpr mice produced 
markedly  higher  concentrations  of NO  than  those  from 
age-matched  BALB/c  or  MRL/+  mice  when  cultured 
with IL-12 and LPS (Fig. 3,  a-c). Nitrite was detectable in 
the culture supernatant after 2  d  and continued to increase 
up to day 6  (Fig. 3 a). NO  production was both IL-12 and 
LPS dependent (Fig. 3, b and c). High concentrations of ni- 
trite were also detected in cultures of peritoneal cells from 
MRL/Ipr mice  (Fig.  3,  d  and  e).  NO  production  in  the 
present system is  dependent  on  the  adherent  cell popula- 
tion  (>90%  macrophages)  and  barely  detectable  in  the 
nonadherent cell population. However, removal of nonad- 
herent  cells significantly reduced  (by 70-82%)  the  IL-12- 
induced NO  production  (Fig.  3 J~.  This suggests that  the 
IL-12-driven NO  synthesis was via its effect on nonadher- 
ent cells. 
Since  IFN-',/  and  IL-12  are  known  to  induce  each 
other's  synthesis,  we  then  determined  whether  the  en- 
hanced  production  of NO  by  spleen  and  peritoneal cells 
from MRL/Ipr mice activated by IFN-~/and LPS was IL-12 
method. (a and d) Kinetics of NO production with 1 ~g/ml LPS plus 10 ng/ml rlL-12. (b and e) show LPS dose-responses with 10 ng/ml IL-12 at days 
6 and 4, respectively. (c) IL-12 dose-response with 1 Ixg/m-t  LPS at day 6. (f) Induction of NO production by IL-12/LPS or IFN-~//LPS by adherent 
and nonadherent peritoneal cells from MRL/Ipr  mice. Nonadherent cells were separated from adherent cells by plastic adhesion and cultured in separate 
wells with fixed doses of LPS (1 Izg/ml) and IL-12 (10 ng/ml) or IFN-'y (50 U/ml). Data shown are nitrite concentrations as percentage of the total un- 
separated cells in the control cultures (mean of triplicates). (*P <0.05,  *'P <0.01). 
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Figure 5.  Inhibition oflL-12/ 
LPS-induced NO production by 
antibodies to IL-12, IFN-3', and 
TNF-(x,  and  by  L-NMMA. 
Pooled spleen  (from  two  mice, 
a) or peritoneal (from five mice, 
b) cells from 2-3-mo-old MR.L/ 
lpr mice were stimulated for 6 or 
4 d, respectively, with rlL-12 (10 
ng/nfl) and LPS (1  p~g/ml) with 
or without addition ofpolyclonal 
antibodies (50  ~g/ml)  to mouse 
IL-12,  IFN-%  TNF-c~,  IFN-~/ 
and  TNF-~x,  or control normal 
rabbit  IgG  (NR  IgG).  In  some 
spleen cell  cultures,  a  NOS  in- 
hibitor,  L-NMMA  or  its  inert 
enanfiomer  control  I)-NMMA 
(500  p.M)  were  added.  Data 
shown  are  mean  and  SD  of 
triplicate  cultures  (*P  <0.05, 
**P <0.01).  Similar results  were 
obtained from four experiments. 
(Dotted  line, b) Nitrite level in the 
cultures  of peritoneal cells  with 
LPS alone. 
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Figure  6.  IL-12/LPS-induced  IFN-'y 
production  in  normal  and  lupus mice. 
Pooled spleen cells  from age- and sex- 
matched MP,.L/Ipr, MR.L/+, or BALB/c 
mice  (n  =  3)  were  stimulated  with 
IL-12 and LPS for 3  d  and IFN-y pro- 
duction was determined by ELISA.  (a) 
Dose-response  studies  of  IL-12  with 
1 Izg/ml LPS; (b) dose-response studies of 
LPS with 10 ng/ml IL-12, IFN-'y levels 
in the unstimulated cultures were  <35 
pg/ml. Data shown are mean and SD of 
triplicates cultures. 
dependent.  Spleen  and  peritoneal  cells  were  stimulated 
with IFN-~/  and LPS as above in the presence of a rabbit 
anti-IL-12 antiserum. The production of NO by these cells 
was  markedly inhibited by the  antiserum but  not by the 
control preimmune serum (Fig.  4). The inhibition was in- 
complete.  This  was  because  IFN-y  and  LPS  can be  ex- 
pected to  directly activate macrophages  to  produce  NO. 
The ability of an anti-IL-12 antibody to inhibit NO  syn- 
thesis  also  indicated that the  IL-12 detected by ELISA in 
the culture supernatants of cells activated with IFN-',//LPS 
(e.g., Fig. 2) was not due to the IL-12 p40 homodimer. 
IL-12/LPS-induced  NO  Production Involves IFN-T  and 
TNF-c~.  Production of NO by spleen and peritoneal cells 
from MR_L/lpr mice activated with IL-12 and LPS can be 
completely abrogated by anti-IL-12 antibody, markedly in- 
hibited  by  anti-IFN-'g  antibody,  and  was  marginally  af- 
fected by anti-TNF-ot antibody, but was  further inhibited 
by the  combination of anti-IFN-y and anti-TNF-e~ anti- 
bodies  (Fig.  5),  suggesting  that  IL-12/LPS-induced NO 
synthesis may be via IFN-~/and TNF-eL. However, there was 
no direct correlation between NO  synthesis and the level 
of IFN-'y produced in cultures of spleen cells from MRL/ 
lpr, MR.L/+,  or BALB/c mice when stimulated with IL- 
12 and LPS under identical conditions (Fig. 6, as compared 
to Fig.  3, b and c). Thus, whereas cells from MR.L/Ipr mice 
produced a high concentration of NO and those from the 
lOO 
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Figure  7.  IL-12/LPS-induced  NO  synthesis involves 
NK and T  cells. Pooled peritoneal cells from two MP.L/lpr 
mice  (5-mo-old)  were  pretreated with  antibodies against 
CD4, CD8, NK cell marker 5E6, Thyl.2, or NK 5E6 plus 
Thyl.2 and then followed by incubation with rabbit serum 
as the source of complement. The cells  were then stimu- 
lated for 4 d with rlL-12 (10 ng/ml) and LPS (1 txg/ml), or 
cultured in medium only as unstimulated control. Data are 
from one of two similar experiments and are expressed as 
percentage of NO concentration in the control cultures of 
stimulated cells without pretreatment (mean +  SD, n =  3, 
*P <0.05, **P <0.01). 
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amount  of NO,  cells  from  the  BALB/c  mice  produced 
markedly higher concentrations of IFN-~/than those pro- 
duced  by cells  from MRL/Ipr mice  which  was  indistin- 
guishable from those of MRL/+  mice. Spleen cells from 
BALB/c  mice also  produced markedly higher concentra- 
tions  of IFN-~/  and  higher  numbers  of IFN-~/--secreting 
cells  than those from MRL/Ipr mice when cultured with 
the T  cell mitogen, Con A  (2.5  ~g/ml), over an extended 
period  (up  to  120  h)  as  detected  by  ELISA  and  by 
ELISPOT (data not shown). 
IL-I2-induced  NO  Synthesis Involves NK  and  T  Cells. 
To determine the cell types involved in the enhanced NO 
synthesis, cell-depletion experiments were carried out in vitro 
using  cytolytic antibodies  and  complement.  Depletion of 
Thyl.2  +  cells  partially reduced NO  production,  whereas 
depletion of  NK cells almost completely abrogated the pro- 
duction  of NO  by peritoneal  cells  from MRL/Ipr mice 
stimulated  with  IL-12  and  LPS  (Fig.  7).  Depletion  of 
CD4 + or CD8 + cells alone had only a modest effect. Since 
some NK cells also express CD8 and Thyl.2 antigens (25), 
it is likely that IL-12-induced NO synthesis involves mainly 
NK cells in addition to the adherent population. 
Evidence for the Enhanced IL-12 Synthesis in MRL/Ipr Mice 
In Vivo.  To confirm the in vitro observations of enhanced 
IL-12 activity in the lupus model, experiments were carried 
out to measure serum levels of IL-12, IFN-% and TNF-ot 
in mice of different age and compared with those of sex- 
and age-matched MRL/+ and BALB/c control mice. Fig. 8 
shows that serum IL-12 levels were markedly higher in the 
Ipr mice,  especially in  the  old  mice  with  clinical  disease 
compared with controls (12-fold in 5-8-too-old mice). This 
was in parallel with the elevated levels of nitrite/nitrate in 
the  serum  (Fig.  1 a).  Treatment of young  (1-2-too-old) 
mice with LPS for as little as 2  h  resulted in significantly 
higher serum IL-12 levels in MRL/Ipr mice compared with 
similarly treated control MRL/+  mice  (Fig.  8  c).  Serum 
IFN-~/  and  TNF-a  were found to  be low,  variable,  and 
comparable (data not shown). 
rlL-12 Accelerates Autoimmune  Disease in MRL/lpr Mice. 
To investigate directly the role oflL-12 in the induction of 
autoimmune disease, young (3-wk-old) MRL/Ipr mice were 
given  daily intraperitoneal injections  of rlL-12  (300  ng/ 
mouse/day)  or a  similar volume of PBS for 9  wk.  Mice 
were then killed and the histopathology of the kidney ex- 
amined. Gross morphology of the kidneys from the IL-12- 
treated mice had a pale waxy surface and were firmer on 
sectioning,  whereas  those  from the  control PBS-injected 
mice appeared normal.  Histological examination revealed 
enlarged glomeruli with significant glomerular and mesan- 
gial hypercellularity in the IL-12-treated group. In particu- 
lar, most of  the IL-12-treated group showed severe damage 
to the glomeruli, with thickening of the Bowman's capsule 
basement membrane and tuft-to-capsule adhesions and pro- 
tein casts (Fig.  9 c) which were largely absent or scanty in 
the PBS-treated group (Fig. 9 a). In contrast, pyelonephritis 
with  extensive vasculitis  and  infiltration of mononuclear 
cells at the kidney medullary region (Fig.  9 b) was promi- 
1455  Huang et al. 
nent in all the mice in the PBS-treated group. These changes 
were minimal in the IL-12-treated mice (Fig. 9 d). 
Spleen cells from the rlL-12-treated mice showed a sig- 
nificantly higher percentage ofCD3 § (51.5 vs 44.5%, P  = 
0.02,  n  =  5),  CD8 + (9.2 vs 5.3%,  P  =  0.02)  and double 
negative (22.6 vs 17.3%,  P  =  0.02) T  cells than those from 
untreated mice. There was, however, no significant differ- 
ence in the spleen weight or the percentage of CD4 + T 
cells in the spleen cell populations between the two groups. 
There was also no significant difference in the anti-ss or ds 
DNA antibody (total antibody as well as IgM and IgG iso- 
type) concentrations in the serum between treated and un- 
treated  mice  (data  not  shown).  However,  serum  IFN-3J 
(16.5  -+ 3.8 vs 5.2  +  1.4 pg/ml, P  =  0.0189) and nitrite/ 
nitrate (54.2  +  2.6 vs 29.6  -  3.0 IxM,  P  =  0.0304) were 
elevated in the IL-12-treated mice compared with those of 
PBS-treated mice. 
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Elevated  serum IL-12  levels in  untreated and LPS-treated 
MI~L/lpr mice. Serum IL-12 levels in untreated (a) young (I-2 mo) and 
(b) old (5-8 too), and in (c) LPS-treated young (1-2 too) MRL/Ipr  mice. 
Control mice were sex- and age-matched MR,  L/+ or BALB/c mice. For 
the LPS treatment, a total of six groups of mice (four per group) were in- 
jected (i.v.  tail vein) with 50 or 500 ng per mouse of LPS in 0,1 ml PBS 
or PBS  alone as indicated.  Serum samples were  collected 2  h  after the 
treatment and IL-12 levels were determined. All samples were assayed in- 
dividually by ELISA; the statistical  significance of differences between lu- 
pus and the control strains of the same age groups is indicated (*P <0.05). 1456  IL-12 and Nitric Oxide in Autoimraune Disease Figure 10.  Schematic  representation of the possible mechanism for the 
induction  of renal pathology (glomerulonephritis) in MP,  L/Ipr mice by 
enhanced IL-12 production and NO synthesis (for details see text). 
It is interesting  to note  that treatment  of MILL/+  mice 
with  IL-12  did  not  induce  any detectable  renal pathology 
(glomerulonephritis  or  proteinuria,  data  not  shown),  sug- 
gesting  that  MRL/lpr mice  are  genetically  predisposed  to 
the  effect of IL-12.  However,  treatment  of MRL/Ipr mice 
(starting  age:  2  mo)  with  a  sheep  anti-mouse  IL-12  anti- 
body  (sheep  no.  7,  100  ~g/mouse  i.p.,  weekly for 7  wk) 
led  to  a  initial  reduction  of proteinuria  followed  by a  re- 
bound  (data  not  shown)  possibly due  to  increased  forma- 
tion  of immune  complexes  resulting  from  repeated  injec- 
tion of foreign proteins. 
Discussion 
Data presented here demonstrate that serum from MILL/ 
lpr mice  contained  significantly  higher  concentrations  of 
IL-12  with  or without  treatment  with  LPS  in  vivo  com- 
pared with those of similarly treated control MR.L/+  mice. 
In addition,  spleen and peritoneal cells from MRL/lpr mice 
produced  significantly higher  concentrations  of IL-12 than 
MILL~+  or  BALB/c  mice  in  response  to  activation  by 
IFN-~/and LPS in vitro.  Furthermore,  cells from MiLL/Ipr 
mice were  more  responsive  to  IL-12  and  LPS,  producing 
higher  concentrations  of NO  than  those  from the  control 
MILL/+  mice.  Finally,  daily injection  ofrlL-12  led to ac- 
celerated glomerulonephritis  in the MRL/Ipr mice but not 
in the MR.L/+  mice. 
These  results  suggest  a  causal  relationship  between  en- 
hanced capacity to produce IL-12 and the spontaneous auto- 
immune disease in this model of SLE as depicted schemati- 
cally in Fig.  10. An earlier report (5)  demonstrated that NO 
is a  critical  mediator  of the  autoimmune  disease in MRL/ 
lpr mice.  It has  also been  documented  that  many autoim- 
mune  animal  models  including  the  lupus  MRL  strain  of 
mice do  not  develop  autoimmune  disease  when  kept in  a 
germ-free environment  (26,  27),  consistent  with  our find- 
ing that LPS  and  IFN-~/  are required  for the  activation  of 
macrophages  to  produce  high  concentrations  of NO  and 
IL-12, which is produced by monocyte/macrophages  (28). 
In contrast to normal MRL/+  or BALB/c  mice, the pro- 
duction of NO  in the MRL/lpr mice is further exaggerated 
by the high  concentration  of IL-12 produced  by activated 
macrophages.  IL-12  activates  NK  and  T  cells  to  produce 
IFN-~/and  perhaps  other yet unidentified  factor(s)  which, 
together with LPS, further enhance NO synthesis. This cycle 
of amplification produces exaggerated levels of NO  leading 
to the pathology.  This is consistent with the delayed onset 
of NO  synthesis  in the  cultures  activated with  IL-12  (Fig. 
3, requiring 4-6 d for optimal production of NO). The ac- 
tivation of NK and T  cells by IL-12 for the production  of 
IFN-~/  has  been  well  documented  (29-31).  However,  in 
the  present  system,  there  was  a  lack  of direct  correlation 
between enhanced NO  synthesis and IFN-~/production  by 
MtLL/lpr and control MILL/+  and BALB/c mice. Never- 
theless, IFN-~ and TNF-o~ were required for IL-12-driven 
NO  synthesis.  It is  therefore  hkely  that  an  additional  fac- 
tor(s)  produced  by  IL-12-activated  NK  or  T  cells  is  re- 
quired to synergize with IFN-~/for the production  of high 
concentrations  of NO.  NK cell activity is known  to be al- 
tered in MILL/lpr mice.  However,  this was based on their 
lytic activity rather than their activity to produce  IFN-% 
IL-12 is essential for the differentiation of the Thl  subset 
oft  cells (32-34).  It is also a powerful adjuvant for the in- 
duction of protective immunity against diseases such as cu- 
taneous leishmaniasis  (35)  in which  Thl  cells are the main 
protective  mechanism  (for reviews  see  references  36,  37). 
Our  results  indicate  that  excessive production  of IL-12 or 
the administration  ofrlL-12  can cause autoimmune  disease 
in susceptible mice, demonstrating  the negative side  of the 
therapeutic  use of IL-12.  This is consistent  with a  number 
of recent  reports showing  that administration  of IL-12 in- 
duced:  (a) earlier onset of insulin-dependent  diabetes mellitus 
in female NOD  mice  (38);  (b) more severe and prolonged 
Figure 9.  Effects  of IL-12 treatment of  MRL/Ipr  mice on renal pathology. Photomicrographs of kidney sections from MILL/lpr  mice (3-mo-old) show- 
ing two essentially normal glomenlli in the kidney cortex ofa PBS-treated control mouse (a); and severe glomerulonephritis in the cortical region of a 
IL-12-treated mouse, including structural damage to two enlarged glomeruli with hypercellularity  and adhesion (c), as well as protein casts in the tubules (c 
and d, arrows).  In contrast, histological examination of the medullary region shows severe pyelonephritis in the PBS-treated mouse (b) featuring extensive 
mononuclear cell infiltration in the perivascular interstitium, which is, however, markedly reduced in the IL-12-treated mouse (d). Periodic Acid-Schiff 
stain, 5<250 (a and c), ￿  (b and d). 
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cephalomyelitis  (39);  and  (c)  destructive  collagen-induced 
arthritis  (40).  Our study here demonstrates that the patho- 
genic effect oflL-12 in the lupus model is likely to be due 
to the increased production of NO.  This finding not only 
advances our knowledge  of the pathogenesis  of this lupus 
model (and by extension  to SLE), it also suggests two po- 
tential means of therapeutic intervention of the progression 
of this  disease:  neutralization  of IL-12  or  inhibition  of 
iNOS. 
Glomerulonephritis  is a severe complication of the renal 
involvement  which  is  the  major  cause  of pathology  and 
death in SLE (18, 41). Although it is generally believed that 
the renal pathology is due to autoantibody production, im- 
mune complex deposition and complement activation, slow 
infections  have  been  shown  to play an  important  role  in 
triggering these autoimmune responses in many models of 
autoimmune disorders  (26). We observed here that IL-12- 
treated  mice  had  clearly  reduced  pyelonephritis  which  is 
known  to be  commonly induced  by infections  (42).  Our 
results  suggest  that  IL-12  might  have  strengthened  the 
host's  defense  against  infection  in  these  mice  which  are 
otherwise  immunodeficient  (43-45).  Thus,  treatment  of 
the  autoimmune  disease  aiming at neutralization  of IL-12 
may weaken the host immune response, leading to uncon- 
trolled infection. These results therefore demonstrated that 
IL-12 is beneficial in controlling infections.  However,  ex- 
cessive production of lL-12, as in the lupus mice, will lead 
to severe immunopathology. 
MRL/Ipr mice differ from the MRL/+  mice in the im- 
pairment of transcription  of the gene encoding Fas antigen 
by insertion  of a transposable  element into  the  second in- 
tron of the gene  (46).  However,  Ipr is not a null mutation 
and the inhibition of Fas expression is incomplete (47). The 
relationship  between  the impaired fas gene expression  and 
enhanced IL-12 and NO production by the MRL/Ipr mice 
is at present unclear, but amenable to experimental investi- 
gation. 
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